Meir Schechter

866 total citations
30 papers, 410 citations indexed

About

Meir Schechter is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Meir Schechter has authored 30 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in Meir Schechter's work include Diabetes Treatment and Management (17 papers), Diabetes Management and Research (9 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Meir Schechter is often cited by papers focused on Diabetes Treatment and Management (17 papers), Diabetes Management and Research (9 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Meir Schechter collaborates with scholars based in Israel, United States and Netherlands. Meir Schechter's co-authors include Ronit Sharon, Ofri Mosenzon, Hiddo J.L. Heerspink, Priya Vart, Lawrence A. Leiter, Lubov Nathanson, Itamar Raz, Ilan Yanuv, Aliza Rozenberg and Cheli Melzer Cohen and has published in prestigious journals such as Journal of Biological Chemistry, Annals of Internal Medicine and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Meir Schechter

27 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Meir Schechter Israel 12 185 124 85 83 74 30 410
Nobuyuki Koriyama Japan 13 109 0.6× 37 0.3× 45 0.5× 101 1.2× 112 1.5× 29 377
Ron Liebkind Finland 12 92 0.5× 112 0.9× 26 0.3× 73 0.9× 31 0.4× 26 530
Andreia Gonçalves Portugal 12 187 1.0× 24 0.2× 38 0.4× 136 1.6× 79 1.1× 16 497
Lars Kärvestedt Sweden 9 175 0.9× 51 0.4× 100 1.2× 89 1.1× 71 1.0× 12 332
Ann‐Cathrin Koschker Germany 9 348 1.9× 35 0.3× 54 0.6× 81 1.0× 267 3.6× 18 612
Magalie Haissaguerre France 15 486 2.6× 87 0.7× 48 0.6× 87 1.0× 431 5.8× 47 875
Takahisa Deguchi Japan 10 75 0.4× 60 0.5× 77 0.9× 89 1.1× 30 0.4× 25 295
Nao Hasuzawa Japan 10 69 0.4× 21 0.2× 73 0.9× 115 1.4× 71 1.0× 37 359
T. Pohlmann Germany 8 109 0.6× 53 0.4× 149 1.8× 63 0.8× 132 1.8× 9 391
G. Galimberti Italy 7 86 0.5× 152 1.2× 143 1.7× 63 0.8× 52 0.7× 14 331

Countries citing papers authored by Meir Schechter

Since Specialization
Citations

This map shows the geographic impact of Meir Schechter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meir Schechter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meir Schechter more than expected).

Fields of papers citing papers by Meir Schechter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meir Schechter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meir Schechter. The network helps show where Meir Schechter may publish in the future.

Co-authorship network of co-authors of Meir Schechter

This figure shows the co-authorship network connecting the top 25 collaborators of Meir Schechter. A scholar is included among the top collaborators of Meir Schechter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meir Schechter. Meir Schechter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Cohen, Cheli Melzer, et al.. (2025). Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes. Diabetes Research and Clinical Practice. 222. 112086–112086. 1 indexed citations
5.
6.
Cohen, Cheli Melzer, Meir Schechter, Aliza Rozenberg, et al.. (2023). Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease. Clinical Journal of the American Society of Nephrology. 18(9). 1153–1162. 11 indexed citations
7.
Vart, Priya, Jawad H. Butt, Niels Jongs, et al.. (2023). Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. The Journals of Gerontology Series A. 79(2). 25 indexed citations
8.
Chan, Kam Wa, Meir Schechter, Niels Jongs, et al.. (2023). Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease. Kidney International. 104(6). 1219–1226. 8 indexed citations
9.
Schechter, Meir, Cheli Melzer Cohen, Ilan Yanuv, et al.. (2022). Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. Cardiovascular Diabetology. 21(1). 104–104. 16 indexed citations
10.
Tye, Sok Cin, Sieta T. de Vries, Johannes F.E. Mann, et al.. (2022). Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. Frontiers in Pharmacology. 13. 786767–786767. 5 indexed citations
11.
Grigoletto, Jéssica, Meir Schechter, & Ronit Sharon. (2022). Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains. Life. 12(1). 63–63. 4 indexed citations
12.
Bardugo, Aya, Estela Derazne, Inbar Zucker, et al.. (2021). Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. The Journal of Clinical Endocrinology & Metabolism. 106(9). e3426–e3435. 9 indexed citations
13.
Mosenzon, Ofri, Stefano Del Prato, Meir Schechter, et al.. (2021). From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes. Cardiovascular Diabetology. 20(1). 92–92. 38 indexed citations
14.
Schechter, Meir & Ronit Sharon. (2021). An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinson’s Disease. Journal of Parkinson s Disease. 11(4). 1725–1750. 6 indexed citations
15.
Schechter, Meir, Cheli Melzer Cohen, Aliza Rozenberg, et al.. (2021). Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovascular Diabetology. 20(1). 169–169. 17 indexed citations
16.
Schechter, Meir, Jéssica Grigoletto, Hava Glickstein, et al.. (2020). A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease. Molecular Neurodegeneration. 15(1). 24–24. 20 indexed citations
17.
Schechter, Meir, et al.. (2020). α-Synuclein facilitates endocytosis by elevating the steady-state levels of phosphatidylinositol 4,5-bisphosphate. Journal of Biological Chemistry. 295(52). 18076–18090. 35 indexed citations
18.
Schechter, Meir, et al.. (2020). α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription. iScience. 23(3). 100910–100910. 42 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nobuyuki Koriyama Breakdown of academic impact, for papers by Ron Liebkind Breakdown of academic impact, for papers by Andreia Gonçalves Breakdown of academic impact, for papers by Lars Kärvestedt Breakdown of academic impact, for papers by Ann‐Cathrin Koschker Breakdown of academic impact, for papers by Magalie Haissaguerre Breakdown of academic impact, for papers by Takahisa Deguchi Breakdown of academic impact, for papers by Nao Hasuzawa Breakdown of academic impact, for papers by T. Pohlmann Breakdown of academic impact, for papers by G. Galimberti
Rankless by CCL
2026